Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
RATIONALE: The Scleroderma Lung Study enrolled 158 patients with scleroderma-related interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although treatment-related benefits in pulmonary function, skin scores, and patient-centered outcomes were demonstrated after 1 year of therapy, the duration of benefit beyond 1 year was unclear. OBJECTIVES: A second year of follow-up was performed to determine if these effects persisted after stopping treatment. METHODS: A detailed analysis of data obtained over the two years of the study was performed. MEASUREMENTS AND MAIN RESULTS: Using a longitudinal joint model, we analyzed FVC, total lung capacity, transitional dyspnea index, Rodnan skin scores, and the Health Assessment Questionnaire-Disability Index during the second year, after adjusting for baseline values, baseline fibrosis score, and nonignorable missing data. Evaluable subjects (72 CYC; 73 placebo) included 93 who completed all visits plus 52 who completed at least 6 months of therapy and returned at 24 month or had their 24-month data imputed. The beneficial effects of CYC on pulmonary function and health status continued to increase through 18 months, after which they dissipated, whereas skin improvements dissipated after 12 months. In contrast, the positive effect on dyspnea persisted through 24 months. Adverse events were uncommon. CONCLUSIONS: One year of CYC improved lung function, skin scores, dyspnea, and health status/disability, effects which either persisted or increased further for several months after stopping therapy. However, except for a sustained impact on dyspnea, all of these effects waned and were no longer apparent at 24 months. Treatment strategies aimed at extending the positive therapeutic effects observed with CYC should be considered. Clinical trial registered with www.clinicaltrials.gov (NCT 000004563).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Standardization of Spirometry, 1994 Update. American Thoracic Society.
(1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.3.7663792 · Cited by 6,594
Analysis of Incomplete Multivariate Data
Booth, D. E. (2000) · Technometrics · doi:10.1080/00401706.2000.10486013 · Cited by 5,627
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
Masi, A. T., & Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230510 · Cited by 4,898
Robust Regression: Asymptotics, Conjectures and Monte Carlo
Huber, P. J. (1973) · The Annals of Statistics · doi:10.1214/aos/1176342503 · Cited by 2,328
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationReference spirometric values using techniques and equipment that meet ATS recommendations.
Terrin, M. (1981) · PubMed · doi:10.1164/arrd.1981.124.6.763c · Cited by 1,374
Busse, W., Corren, J., Lanier, B. Q., McAlary, M., Fowler-Taylor, A., Cioppa, G. D., van As, A., & Gupta, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.117880 · Cited by 1,307
Mahler, D. A., Weinberg, D. H., Wells, C. K., & Feinstein, A. R. (1984) · Chest · doi:10.1378/chest.85.6.751 · Cited by 1,292
Clements, P. J., Lachenbruch, P. A., Siebold, J., White, B., Weiner, S. J., Martin, R. W., Weinstein, A., Weisman, M. H., Mayes, M. D., & Collier, D. H. (1995) · PubMed · Cited by 874
Self-citationHoyles, R. K., Ellis, R. W., Wellsbury, J., Lees, B., Newlands, P., Goh, N. S. L., Roberts, C., Desai, S., Herrick, A. L., McHugh, N. J., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22204 · Cited by 732 · cited 1×
“One alternative approach that has been tried involved a trial of CYC administered by intravenous infusion monthly for 6 months (to minimize the risk of hemorrhagic cystitis associated with the oral route), followed by azathioprine versus placebo in 45 patients with active fibrosing alveolitis due to SSc (39).”
MethodReference spirometric values using techniques and equipment that meet ATS recommendations.
Crapo, R. O., Morris, A. H., & Gardner, R. M. (1981) · PubMed · doi:10.1164/arrd.1981.123.6.659 · Cited by 614
Permutation methods: a distance function approach
(2002) · Choice Reviews Online · doi:10.5860/choice.39-3427 · Cited by 611
Crapo, R. O., Hankinson, J., Irvin, C. G., et al. (1995) · American Journal of Respiratory and Critical Care Medicine · Cited by 593
Cyclophosphamide-Induced Cystitis and Bladder Cancer in Patients with Wegener Granulomatosis
Talar-Williams, C., Hijazi, Y. M., Walther, M. M., Linehan, W. M., Hallahan, C. W., Lubensky, I., Kerr, G. S., Hoffman, G. S., Fauci, A. S., & Sneller, M. C. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-5-199603010-00003 · Cited by 537
Severe restrictive lung disease in systemic sclerosis
Steen, V. D., Conte, C., Owens, G. R., & Medsger, T. A. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370903 · Cited by 526
Self-citationSteen, V. D., & Medsger, T. A. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780401110 · Cited by 504
Self-citation(1984) · British Journal of Diseases of the Chest · doi:10.1016/0007-0971(84)90110-4 · Cited by 498
Standardized single breath normal values for carbon monoxide diffusing capacity.
Crapo, R. O., & Morris, A. H. (1981) · PubMed · doi:10.1164/arrd.1981.123.2.185 · Cited by 490
(1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.6.8520796 · Cited by 490
Manning, H. L., & Schwartzstein, R. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332307 · Cited by 472
White, B., Moore, W. C., Wigley, F. M., Xiao, H. Q., & Wise, R. A. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-12-200006200-00004 · Cited by 384
Self-citationRadis, C. D., Kahl, L. E., Baker, G. L., Wasko, M. C. M., Cash, J. M., Gallatin, A., Stolzer, B. L., Agarwal, A. K., Medsger, T. A., & Kwoh, C. K. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380815 · Cited by 314
American Association for Respiratory Care
(2018) · Palgrave Macmillan UK eBooks · doi:10.1007/978-1-349-94186-5_51 · Cited by 286
Guidelines for the measurement of respiratory function
British Thoracic Society (1994) · Respiratory Medicine · doi:10.1016/s0954-6111(05)80346-4 · Cited by 282
Silver, R. M., Warrick, J. H., Kinsella, M., Staudt, L. S., Baumann, M. H., & Strange, C. (1993) · PubMed · Cited by 200
Self-citationTherapy for severe interstitial lung disease in systemic sclerosis. a retrospective study
Steen, V. D., Lanz, J. K., Conte, C., Owens, G. R., & Medsger, T. A. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370904 · Cited by 184
Self-citationBaltus, J., Boersma, J. W., Hartman, A. P., et al. (1983) · Annals of the Rheumatic Diseases · doi:10.1136/ard.42.4.368 · Cited by 152
Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide
Åkesson, A., Scheja, A., Lundin, A., & Wollheim, F. A. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370518 · Cited by 150
Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.
Pakas, I., Ioannidis, J. P. A., Malagari, K. S., Skopouli, F. N., Moutsopoulos, H. Μ., & Vlachoyiannopoulos, P. G. (2002) · PubMed · Cited by 138
Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung.
Behr, J., Vogelmeier, C., Beinert, T., Meurer, M., Krombach, F., König, G., & Fruhmann, G. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.154.2.8756813 · Cited by 131
Cyclophosphamide Pulse Regimen in the Treatment of Alveolitis in Systemic Sclerosis
Giacomelli, R., Valentini, G., Salsano, F., Cipriani, P., Sambo, P., Conforti, M. L., Fulminis, A., Luca, A. D., Farina, G. A., Candela, M., et al. (2019) · The Journal of Rheumatology · doi:10.3899/jrheum.020731.c1 · Cited by 131
Hu, W., Li, G., & Li, N. (2009) · Statistics in Medicine · doi:10.1002/sim.3562 · Cited by 126
Self-citationClements, P. J., Wong, W. K., Hurwitz, E. L., Fürst, D. E., Mayes, M. D., White, B., Wigley, F. M., Weisman, M. H., Barr, W. G., Moreland, L. W., et al. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200103)44:3<653::aid-anr114>3.0.co;2-q · Cited by 107
Self-citationMechanisms and measurement of dyspnea in chronic obstructive pulmonary disease.
Mahler, D. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200509-103sf · Cited by 90
An approach to joint analysis of longitudinal measurements and competing risks failure time data
Elashoff, R. M., Li, G., & Li, N. (2006) · Statistics in Medicine · doi:10.1002/sim.2749 · Cited by 84
Self-citationVárai, G., Earle, L., Jiménez, S. A., Steiner, R. M., & Varga, J. (1998) · PubMed · Cited by 73
Self-citationCyclophosphamide for Scleroderma Lung Disease
Martínez, F. J., & McCune, W. J. (2006) · New England Journal of Medicine · doi:10.1056/nejme068095 · Cited by 61
Permutation Covariate Analyses of Residuals Based on Euclidean Distance
Mielke, P. W., & Berry, K. J. (1997) · Psychological Reports · doi:10.2466/pr0.1997.81.3.795 · Cited by 36
Cited by
Denton, C. P., & Khanna, D. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30933-9 · Cited by 2,212
Self-citationInterstitial Lung Disease in Systemic Sclerosis: A Simple Staging System
Goh, N. S. L., Desai, S. R., Veeraraghavan, S., Hansell, D. M., Copley, S. J., Maher, T. M., Corte, T. J., Sander, C. R., Ratoff, J., Devaraj, A., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-877oc · Cited by 1,230
Update of EULAR recommendations for the treatment of systemic sclerosis
Kowal-Bielecka, O., Fransen, J., Avouac, J., Becker, M., Kulak, A., Allanore, Y., Distler, O., Clements, P., Cutolo, M., Czirjak, L., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209909 · Cited by 1,104
Self-citationTashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J., Arriola, E., Volkmann, E. R., Kafaja, S., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30152-7 · Cited by 1,078
Self-citationAllanore, Y., Simms, R., Distler, O., Trojanowska, M., Pope, J., Denton, C. P., & Varga, J. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.2 · Cited by 876
Self-citation
Metadata
- Authors
- Tashkin, D. P., Elashoff, R., Clements, P. J., Roth, M. D., Furst, D. E., Silver, R. M., Goldin, J., Arriola, E., Strange, C., Bolster, M. B., Seibold, J. R., Riley, D. J., Hsu, V. M., Varga, J., Schraufnagel, D., Theodore, A., Simms, R., Wise, R., Wigley, F., White, B., Steen, V., Read, C., Mayes, M., Parsley, E., Mubarak, K., Connolly, M. K., Golden, J., Olman, M., Fessler, B., Rothfield, N., Metersky, M., Khanna, D., Li, N., Li, G., & for the Scleroderma Lung Study Research Group
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-11-15
- Volume
- 176
- Issue
- 10
- Pages
- 1026-1034
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2147543851
- Cited by
- 464
- References
- 41
- FWCI
- 17.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.